Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Zora Biosciences OY has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to a distinct examiner, Gary W Counts, who is the busiest examiner with 1 pending action. The matter is located within a distinct art unit, representing a highly concentrated prosecution profile.
In this portfolio, all current results depend on a single examiner's review. For the practitioner, this means that the prosecution strategy does not need to account for the diverse perspectives often found in larger biotechnology portfolios. Instead, the focus remains entirely on Gary W Counts and the specific standards of the art unit where the action is pending.
The presence of a single pending action in a specific art unit suggests a very targeted approach to the company's current patent filings. Because there is only a distinct examiner involved, the legal team can develop a deep understanding of his specific requirements and preferences. This singular focus is key to successfully navigating the complexities of the Biotechnology & Pharmaceuticals field for this specific matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COUNTS, GARY W | 1 | 58.9% | +29.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18669809 | LIPIDOMIC BIOMARKERS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE | COUNTS, GARY W | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18669809 | LIPIDOMIC BIOMARKERS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE | COUNTS, GARY W | — |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18669809 | LIPIDOMIC BIOMARKERS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE | COUNTS, GARY W | 1678 | §101§112 | Non-Final OA | — | Pending | May 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZora Biosciences OY has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Gary W Counts has the most, with 1 of Zora Biosciences OY's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
